However, not all patients show tubular aggregates in muscle biopsy (Guergueltcheva et al., 2012), suggesting a need to re‐recognize and summarize the diversity of muscle pathology in patients with CMS associated with GFPT1 mutations. This evidence concerns the gene GFPT1 and congenital myasthenic syndrome.